โ† Home / China SXT Pharmaceuticals, Inc. (SXTC)
Stock Analysis

China SXT Pharmaceuticals, Inc. (SXTC)

SXTC
SXTC ยท Market data
4.58 +22.13%
Track SXTC in your personal workspace Monitor performance, SPY relative strength and WOI View from your watchlist.
Alert me when SXTC price is:
52W Range Position
2%
LOWMIDHIGH
Trend
Mixed
Momentum
Neutral
Updated: 2026-08-18 14:36 UTC
WOI Investment Thesis
Mixed
Confirmation improves above 52.20. Holding above 2.52 keeps the current thesis intact.
โš–๏ธ
โœ“
Fundamentals
Insufficient / Negative
โœ“
Price Structure
Mixed
โ€ข
Momentum
Neutral
ร—
Breakout Confirmation
Pending
Risk Level
Moderate
Analysis Scope
1Y Daily
Key Decision Levels
โœ“
Hold Above
Structure remains valid above support.
2.52
โ†—
Break Above
Confirmation improves above resistance.
52.20
๐ŸŽฏ
Next Objective
Pattern-derived target if setup continues.
โ€”
ร—
Thesis Break
Scenario weakens below invalidation.
Below 2.52
What's Driving SXTC?
๐Ÿ“ˆ Technical recovery is improving
Momentum is Neutral. Watch 52.20 for confirmation and 2.52 for structure risk.
๐Ÿ’ผ Business quality remains relevant
Fundamentals remain relevant. Check growth, profitability, cash flow and balance sheet quality.
โš ๏ธ Key risk remains
losing 2.52 would weaken the current structure.
Full Analysis Workspace
Technical Signal
Waiting for Confirmation
โ–ฒ
No confirmed breakout yet. Watch the next level and momentum behavior.
RSI(14)
72.4
โ—Ž
How to read this setup
The nearest decision zone is framed by support around 2.52 and resistance near 52.20. Clearing resistance would strengthen the constructive case, while a failure through support would damage the present setup.
Price Chart
SXTC โ€” 1D Chart
Open Full Workspace
Business Lens
Financial context is mixed
Financial conditions require selective monitoring.
โ†—
Revenue Growth
Insufficient
โ—
Profitability
Negative
โ‰ˆ
Cash Flow
Insufficient
โš–
Balance Sheet
Strong
๐Ÿ’ต Revenue
829,490
โ‰ˆ Insufficient
๐Ÿ“ˆ Net Income
-802,568
โ†˜ Negative
๐Ÿงฎ EPS (Basic)
-0.25
โ†˜ Negative
China SXT Pharmaceuticals, Inc.